TY - JOUR
T1 - LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
AU - Natkunam, Yasodha
AU - Farinha, Pedro
AU - Hsi, Eric D.
AU - Hans, Christine P.
AU - Tibshirani, Robert
AU - Sehn, Laurie H.
AU - Connors, Joseph M.
AU - Gratzinger, Dita
AU - Rosado, Manuel
AU - Zhao, Shuchun
AU - Pohlman, Brad
AU - Wongchaowart, Nicholas
AU - Bast, Martin
AU - Avigdor, Abraham
AU - Schiby, Ginette
AU - Nagler, Arnon
AU - Byrne, Gerald E.
AU - Levy, Ronald
AU - Gascoyne, Randy D.
AU - Lossos, Izidore S.
PY - 2008/1/20
Y1 - 2008/1/20
N2 - Purpose: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. Patients and Methods: DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. Results: In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. Conclusion: We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.
AB - Purpose: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. Patients and Methods: DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. Results: In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. Conclusion: We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management.
UR - http://www.scopus.com/inward/record.url?scp=38649123973&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.13.0690
DO - 10.1200/JCO.2007.13.0690
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18086797
AN - SCOPUS:38649123973
SN - 0732-183X
VL - 26
SP - 447
EP - 454
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -
